Merck & Company Inc. (new) ($MRK) Stock Forecast: Up 5.5% Today

What is Merck & Company Inc. (new)?

Merck & Co Inc (MRK) is a pharmaceutical company recognized for its cutting-edge drugs and prominent position in the oncology market. Recently, the stock saw a significant upward trend.

Why is Merck & Company Inc. (new) going up?

MRK stock is up 5.5% on May 22, 2026 17:40

• Merck's stock increased by 4.50% after positive Phase III clinical trial outcomes for its lung cancer drug, sacituzumab tirumotecan (sac-TMT), in conjunction with Keytruda. This development instilled confidence among investors regarding the company's oncology projects.
• The EU drug regulator's backing of Merck's Keytruda for new uses signals broader market reach and potential revenue expansion, further enhancing the positive investor sentiment.
• Partnership with Kelun-Biotech in a successful late-stage trial for a lung cancer combination therapy surpassing Keytruda's performance alone showcases Merck's dedication to innovation and market dominance in oncology.
• Notwithstanding challenges such as an unsuccessful trial and analyst revision, Merck's robust Q1 2026 earnings and upcoming oncology data presentations at the ASCO gathering are reinforcing the company's financial strength and strategic direction, propelling the uptrend in its stock value.

MRK Price Chart

MRK Technical Analysis

MRK News

AbbVie, Merck, Astra among winners of EU drug recommendations this week

The EU drug regulator's expert panel has recommended eight new medicines for approval this week, benefiting companies like Merck, AstraZeneca, and AbbVie. Merck's Keytruda, AstraZeneca's Enhertu, and AbbVie's Maviret received positive opinions for new indications, suggesting expanded market access and potential revenue growth. Pending final decisions from the European Commission could significantly impact the future revenue streams for these drugmakers by unlocking new sales volumes for larger or new patient groups.

https://seekingalpha.com/news/4596353-abbvie-merck-astra-among-winners-eu-drug-recommendations

Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Crescent Biopharma (CBIO) has not yet received any FDA approvals for its therapy CR-001, which is being investigated for the treatment of advanced solid tumors. The company recently announced a poster presentation for its ASCEND study of CR-001 at the 2026 ASCO Annual Meeting and previously reported dosing the first patient in its global Phase 1/2 clinical trial for the drug. Crescent Biopharma anticipates multiple data readouts for CR-001 starting in Q1 2027.

https://www.marketbeat.com/stocks/NASDAQ/CBIO/fda-events/

Merck & Co Inc Stock (MRK) Opened Up by 4.50% on May 22: Facts Behind the Movement

Merck & Co Inc (MRK) saw its stock open up by 4.50% on May 22, driven primarily by positive Phase III clinical trial results for its sacituzumab tirumotecan (sac-TMT) in combination with Keytruda for lung cancer. Upcoming extensive oncology data presentations at the ASCO meeting and strong Q1 2026 earnings that surpassed expectations further contributed to the optimistic investor sentiment. Despite recent setbacks like a failed trial and a downgrade from one analyst, the company's financial performance and strategic pipeline developments are buoying its stock price.

https://www.tradingkey.com/news/market-movers/261922883-market-movers-mrk-20260522

Merck & Co., Inc. stock (US58933Y1055): Key cancer drug data and dividend profile in focus

Merck & Co., Inc. is gaining attention for its strong oncology data, particularly concerning its blockbuster cancer therapy Keytruda, and its consistent dividend payouts. The article details Merck's business model, emphasizing its focus on R&D, product diversification, and robust financial profile, while also noting the risks associated with its reliance on Keytruda. Key updates on its pipeline and significance for US investors are also highlighted.

https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-inc-stock-us58933y1055-key-cancer-drug-data-and/69401994

Merck and Kelun's lung cancer combo bests Keytruda (MRK:NYSE)

A collaboration between Merck and Chinese biopharma company Kelun-Biotech has yielded promising results from a late-stage trial for lung cancer. Their antibody drug conjugate, when used with Keytruda, demonstrated superior performance compared to Keytruda alone. This development could represent a significant advancement in lung cancer treatment.

https://seekingalpha.com/news/4596242-merck-and-keluns-lung-cancer-combo-bests-keytruda

Trending Today

Sonos Inc. ($SONO) Stock Forecast: Up 5.2% Today

HP Inc. ($HPQ) Stock Forecast: Up 15.6% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.2% Today

GlobalFoundries Inc. ($GFS) Stock Forecast: Up 6.4% Today

Ford Motor Company ($F) Stock Forecast: Up 8.7% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 12.4% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 11.0% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.6% Today

Steel Dynamics Inc. ($STLD) Stock Forecast: Up 5.6% Today

NetApp Inc. ($NTAP) Stock Forecast: Up 14.7% Today

Merck & Company Inc. (new) Price History

03.01.2026 - MRK Stock was up 2.0%

• Merck & Co. (MRK) stock saw an uptick following the release of robust Q4 2025 financial results and positive FY 2026 earnings outlook.
• Optimism surrounds Merck's acquisitions and broad pipeline diversification, especially looking beyond the exclusivity of Keytruda, driving the positive market sentiment.
• An educational campaign by Bristol Myers Squibb and Johnson & Johnson about the factor XIa pathway may be influencing the upward movement, shining a light on the potential of novel anticoagulants for cardiovascular and thromboembolic conditions.
• Positive remarks by Jim Cramer regarding Merck's future prospects and its expansion beyond Keytruda are likely bolstering investor confidence in the company's growth trajectory.

03.01.2026 - MRK Stock was up 6.2%

• Reported impressive Q4 2025 sales and profit figures, beating analyst estimates, driven by strong demand for KEYTRUDA and benefits from recent acquisitions.
• Despite the positive earnings, the cautious 2026 outlook, lower-than-expected guidance, and concerns over the impact of the Cidara acquisition led to initial pre-market stock decline.
• Analysts and experts remain optimistic about Merck's strategic acquisitions, diversified pipeline, and upcoming catalysts, highlighting the company's long-term potential.
• The market seems to be balancing Merck's current financial performance with future growth prospects and potential challenges in specific product sales, such as GARDASIL in China.

21.03.2026 - MRK Stock was down 5.1%

• Positive updates on Moderna's investigational mRNA therapeutics, particularly in melanoma treatment, may have overshadowed Merck's position in the market, leading to a bearish sentiment.
• The 52-week low hit by Boston Scientific's stock could have raised concerns about the overall performance of healthcare-related companies, impacting Merck's stock negatively.
• Despite positive analyst sentiment and institutional investments in Merck, the setback in a Phase 3 cancer drug trial might have contributed to the bearish movement as investors reevaluated the company's future prospects.
• The increased stake by Novem Group and the acquisition by SageGuard Financial Group LLC could indicate confidence in Merck's long-term potential, but the market may have reacted more strongly to the recent trial setback, resulting in the bearish trend.

22.04.2026 - MRK Stock was up 5.5%

• Merck's stock increased by 4.50% after positive Phase III clinical trial outcomes for its lung cancer drug, sacituzumab tirumotecan (sac-TMT), in conjunction with Keytruda. This development instilled confidence among investors regarding the company's oncology projects.
• The EU drug regulator's backing of Merck's Keytruda for new uses signals broader market reach and potential revenue expansion, further enhancing the positive investor sentiment.
• Partnership with Kelun-Biotech in a successful late-stage trial for a lung cancer combination therapy surpassing Keytruda's performance alone showcases Merck's dedication to innovation and market dominance in oncology.
• Notwithstanding challenges such as an unsuccessful trial and analyst revision, Merck's robust Q1 2026 earnings and upcoming oncology data presentations at the ASCO gathering are reinforcing the company's financial strength and strategic direction, propelling the uptrend in its stock value.

22.04.2026 - MRK Stock was up 7.6%

• The bullish movement in Merck's stock is linked to positive operating updates and encouraging results from oncology trials. Particularly, the successful combination therapy with Moderna has shown a promising reduction in the risk of melanoma spreading.
• Investor confidence in Merck's potential for growth and innovation received a boost with an investment from Keudell Morrison Wealth Management.
• The collaboration with Exelixis for a colorectal cancer trial demonstrates Merck's dedication to broadening its portfolio and seeking new revenue streams, which has resonated positively with investors.
• Despite varied sentiments from analysts, the overall favorable developments and strategic partnerships have driven Merck's stock price upwards, indicating an optimistic outlook for the company's future.

22.04.2026 - MRK Stock was up 6.4%

• The rise in Merck & Co Inc's stock is linked to the successful Phase III clinical trial outcomes for its sacituzumab tirumotecan (sac-TMT) with Keytruda in treating lung cancer, showcasing the company's dedication to advancing cancer treatments.
• The anticipation of substantial oncology data releases at the ASCO meeting and the strong Q1 2026 earnings surpassing expectations have boosted investor confidence, underlining the company's solid financial performance and strategic pipeline advancements.
• Collaborations with Kelun-Biotech and Moderna, demonstrating promising results in late-stage trials for lung cancer and melanoma, have added to the positive outlook on Merck & Co Inc, reinforcing its role in the oncology sector.
• Despite recent challenges and varied analyst opinions, the company's emphasis on research and development, product diversification, and regular dividend payments have built trust among investors, propelling the stock price upwards.

30.02.2026 - MRK Stock was down 1.4%

• Merck (MRK) experienced a bearish movement despite positive news surrounding its recent acquisition of Terns Pharmaceuticals and strong Q4 earnings.
• The increased investment by WESPAC Advisors LLC did not seem to positively impact MRK's stock performance today.
• The growth in the Non-Muscle Invasive Bladder Cancer (NMIBC) market, where Merck is a key player, did not translate into a positive market movement for the company.
• Jim Cramer's advice to "stay the course" with MRK stock did not prevent the bearish trend today, indicating other market factors at play.

08.00.2026 - MRK Stock was up 3.3%

• Merck's stock price surged following an upgrade from Wolfe Research to Outperform from Peer Perform, showcasing optimism and confidence in the company's growth outlook.
• Identification as a top long-term growth stock by Zacks Investment Research heightened investor interest in Merck, propelling the stock upwards.
• A strategic partnership between Veeva Systems and BioMarin Pharmaceutical, though unrelated to Merck, underlines industry collaborations that could have a positive impact on market sentiment.
• United Asset Strategies Inc. raised its stake in Merck, indicating institutional confidence in the company's future performance and strategic endeavors.